Pub Date : 2007-01-01Epub Date: 2007-09-02DOI: 10.1016/S1075-8593(06)05008-8
{"title":"Index.","authors":"","doi":"10.1016/S1075-8593(06)05008-8","DOIUrl":"https://doi.org/10.1016/S1075-8593(06)05008-8","url":null,"abstract":"","PeriodicalId":92864,"journal":{"name":"Advances in antiviral drug design","volume":"5 ","pages":"243-251"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1075-8593(06)05008-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37833328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-01-01Epub Date: 2007-09-02DOI: 10.1016/S1075-8593(06)05001-5
Erik De Clercq
More than 40 compounds have been formally licensed for clinical use as antiviral drugs, and half of these are used for the treatment of HIV infections. The others have been approved for the therapy of herpesvirus (HSV, VZV, CMV), hepadnavirus (HBV), hepacivirus (HCV) and myxovirus (influenza, RSV) infections. New compounds are in clinical development or under preclinical evaluation, and, again, half of these are targeting HIV infections. Yet, quite a number of important viral pathogens (i.e. HPV, HCV, hemorrhagic fever viruses) remain in need of effective and/or improved antiviral therapies.
{"title":"Status Presens of Antiviral Drugs And Strategies: Part I: DNA Viruses and Retroviruses.","authors":"Erik De Clercq","doi":"10.1016/S1075-8593(06)05001-5","DOIUrl":"https://doi.org/10.1016/S1075-8593(06)05001-5","url":null,"abstract":"<p><p>More than 40 compounds have been formally licensed for clinical use as antiviral drugs, and half of these are used for the treatment of HIV infections. The others have been approved for the therapy of herpesvirus (HSV, VZV, CMV), hepadnavirus (HBV), hepacivirus (HCV) and myxovirus (influenza, RSV) infections. New compounds are in clinical development or under preclinical evaluation, and, again, half of these are targeting HIV infections. Yet, quite a number of important viral pathogens (i.e. HPV, HCV, hemorrhagic fever viruses) remain in need of effective and/or improved antiviral therapies.</p>","PeriodicalId":92864,"journal":{"name":"Advances in antiviral drug design","volume":"5 ","pages":"1-58"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1075-8593(06)05001-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37833327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-01-01Epub Date: 2007-09-02DOI: 10.1016/S1075-8593(06)05002-7
Erik De Clercq
More than 40 compounds have been formally licensed for clinical use as antiviral drugs, and half of these are used for the treatment of HIV infections. The others have been approved for the therapy of herpesvirus (HSV, VZV, CMV), hepadnavirus (HBV), hepacivirus (HCV) and myxovirus (influenza, RSV) infections. New compounds are in clinical development or under preclinical evaluation, and, again, half of these are targeting HIV infections. Yet, quite a number of important viral pathogens (i.e. HPV, HCV, hemorrhagic fever viruses) remain in need of effective and/or improved antiviral therapies.
{"title":"Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES).","authors":"Erik De Clercq","doi":"10.1016/S1075-8593(06)05002-7","DOIUrl":"https://doi.org/10.1016/S1075-8593(06)05002-7","url":null,"abstract":"<p><p>More than 40 compounds have been formally licensed for clinical use as antiviral drugs, and half of these are used for the treatment of HIV infections. The others have been approved for the therapy of herpesvirus (HSV, VZV, CMV), hepadnavirus (HBV), hepacivirus (HCV) and myxovirus (influenza, RSV) infections. New compounds are in clinical development or under preclinical evaluation, and, again, half of these are targeting HIV infections. Yet, quite a number of important viral pathogens (i.e. HPV, HCV, hemorrhagic fever viruses) remain in need of effective and/or improved antiviral therapies.</p>","PeriodicalId":92864,"journal":{"name":"Advances in antiviral drug design","volume":"5 ","pages":"59-112"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1075-8593(06)05002-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37833331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-01-01DOI: 10.1016/S1075-8593(06)05003-9
J. Žemlička
{"title":"Methylenecyclopropane Analogues of Nucleosides as Anti-herpes Agents","authors":"J. Žemlička","doi":"10.1016/S1075-8593(06)05003-9","DOIUrl":"https://doi.org/10.1016/S1075-8593(06)05003-9","url":null,"abstract":"","PeriodicalId":92864,"journal":{"name":"Advances in antiviral drug design","volume":"5 1","pages":"113-165"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1075-8593(06)05003-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56388019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-01-01DOI: 10.1016/S1075-8593(06)05004-0
K. Hostetler
{"title":"Synthesis and antiviral evaluation of broad spectrum, orally active analogs of cidofovir and other acyclic nucleoside phosphonates","authors":"K. Hostetler","doi":"10.1016/S1075-8593(06)05004-0","DOIUrl":"https://doi.org/10.1016/S1075-8593(06)05004-0","url":null,"abstract":"","PeriodicalId":92864,"journal":{"name":"Advances in antiviral drug design","volume":"5 1","pages":"167-184"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1075-8593(06)05004-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56388032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-01-01DOI: 10.1016/S1075-8593(06)05006-4
J. Heeres, P. Lewi
{"title":"The medicinal chemistry of the DATA and DAPY series of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)","authors":"J. Heeres, P. Lewi","doi":"10.1016/S1075-8593(06)05006-4","DOIUrl":"https://doi.org/10.1016/S1075-8593(06)05006-4","url":null,"abstract":"","PeriodicalId":92864,"journal":{"name":"Advances in antiviral drug design","volume":"101 1","pages":"213-242"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1075-8593(06)05006-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56388065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-01-01DOI: 10.1016/S1075-8593(06)05005-2
M. Perros
{"title":"CCR5 antagonists for the treatment of HIV infection and AIDS","authors":"M. Perros","doi":"10.1016/S1075-8593(06)05005-2","DOIUrl":"https://doi.org/10.1016/S1075-8593(06)05005-2","url":null,"abstract":"","PeriodicalId":92864,"journal":{"name":"Advances in antiviral drug design","volume":"5 1","pages":"185-212"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1075-8593(06)05005-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56388047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2003-01-01DOI: 10.1016/S1075-8593(03)04002-4
D. Hazuda, S. D. Young
{"title":"Inhibitors of human immunodeficiency virus integration","authors":"D. Hazuda, S. D. Young","doi":"10.1016/S1075-8593(03)04002-4","DOIUrl":"https://doi.org/10.1016/S1075-8593(03)04002-4","url":null,"abstract":"","PeriodicalId":92864,"journal":{"name":"Advances in antiviral drug design","volume":"4 1","pages":"63-77"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1075-8593(03)04002-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56387952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2003-01-01DOI: 10.1016/S1075-8593(03)04005-X
Jing Wang, M. Froeyen, P. Herdewijn
{"title":"Six-membered Carbocyclic Nucleosides","authors":"Jing Wang, M. Froeyen, P. Herdewijn","doi":"10.1016/S1075-8593(03)04005-X","DOIUrl":"https://doi.org/10.1016/S1075-8593(03)04005-X","url":null,"abstract":"","PeriodicalId":92864,"journal":{"name":"Advances in antiviral drug design","volume":"4 1","pages":"119-145"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1075-8593(03)04005-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56387989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2003-01-01DOI: 10.1016/S1075-8593(03)04006-1
C. Meier
{"title":"cycloSal-Pronucleotides—Design of the Concept, Chemistry, and Antiviral Activity","authors":"C. Meier","doi":"10.1016/S1075-8593(03)04006-1","DOIUrl":"https://doi.org/10.1016/S1075-8593(03)04006-1","url":null,"abstract":"","PeriodicalId":92864,"journal":{"name":"Advances in antiviral drug design","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1075-8593(03)04006-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56388006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号